TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04471987: A Phase I Study to Evaluate Safety and Early Signs of Efficacy of the Human Monoclonal Antibody-cytokine Fusion Protein IL12-L19L19.

Sponsor: Philogen S.p.A. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,440,280

Rescue Site Savings

+$4,241,160

Unlock Full NCT04471987 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04471987 Rescue Dossier →